DeepMed Research

UNICANCER

🇧🇷Brazil

Country: 🇧🇷Brazil

Ownership: Private

Established: 1964-01-01

Employees: 101

Market Cap: -

Website: http://www.unicancer.fr

Clinical Trials

Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women

Phase 2

Completed

Conditions: Neoadjuvant Operable Breast Cancer

Interventions: Drug: Fluorouracile
Drug: Letrozole
Drug: Epirubicin
Drug: Palbociclib
Drug: Cyclophosphamide

First Posted Date: 2015-03-27

Last Posted Date: 2022-03-15

Lead Sponsor: UNICANCER

Target Recruit Count: 125

Registration Number: NCT02400567

Locations: 🇫🇷
Gustave Roussy, Villejuif, France
🇫🇷
Institut Curie, Paris, France

Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma

Phase 2

Completed

Conditions: Salivary Gland Carcinoma

Interventions: Drug: pazopanib

First Posted Date: 2015-03-19

Last Posted Date: 2019-10-29

Lead Sponsor: UNICANCER

Target Recruit Count: 72

Registration Number: NCT02393820

Locations: 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
CHU Bordeaux, Bordeaux, France
🇫🇷
Gustave Roussy, Villejuif, France

and more 12 locations

A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas

Phase 2

Active, not recruiting

Conditions: Chondroma
Chondrosarcomas
Osteosarcomas
CIC-Rearranged Sarcoma
Ewing Sarcomas

Interventions: Drug: Placebo
Drug: Regorafenib

First Posted Date: 2015-03-17

Last Posted Date: 2024-12-05

Lead Sponsor: UNICANCER

Target Recruit Count: 163

Registration Number: NCT02389244

Locations: 🇫🇷
Hopital Jean Monjoz, Besancon, France
🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷
Centre Francois Baclesse, Caen, France

and more 16 locations

Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)

Phase 2

Completed

Conditions: Collecting Duct Carcinoma (Kidney)

Interventions: Drug: Bevacizumab

First Posted Date: 2015-02-16

Last Posted Date: 2021-03-09

Lead Sponsor: UNICANCER

Target Recruit Count: 36

Registration Number: NCT02363751

Locations: 🇫🇷
Institut de Cancérologie de l'Ouest-Site Paul Papin, Angers, France
🇫🇷
CHU Besançon, Besançon, France
🇫🇷
Centre François Baclesse, Caen, France

and more 16 locations

Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: FEC100
Drug: Docetaxel
Drug: Trastuzumab
Drug: Pertuzumab
Drug: Carboplatin

First Posted Date: 2015-01-15

Last Posted Date: 2024-11-08

Lead Sponsor: UNICANCER

Target Recruit Count: 86

Registration Number: NCT02339532

Locations: 🇫🇷
Centre Paul Strauss, Strasbourg, France
🇫🇷
Institut de Cancerologie de L'Ouest - Site Paul Papin, Angers, France
🇫🇷
Centre Hospitalier Regional Universitaire de Brest - Hôpital Morvan, Brest, France

and more 9 locations

Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer

Phase 3

Completed

Conditions: Inflammatory Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Epirubicin

First Posted Date: 2014-12-24

Last Posted Date: 2021-02-21

Lead Sponsor: UNICANCER

Target Recruit Count: 174

Registration Number: NCT02324088

Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

Phase 2

Active, not recruiting

Conditions: Solid Tumors
Hematologic Cancers
Metastatic Cancers

Interventions: Drug: Vemurafenib

First Posted Date: 2014-12-02

Last Posted Date: 2024-06-07

Lead Sponsor: UNICANCER

Target Recruit Count: 216

Registration Number: NCT02304809

Locations: 🇫🇷
Tredaniel, Paris, France

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: AZD2014
Drug: Anthracyclines
Drug: MEDI4736
Drug: AZD4547
Drug: Taxanes
Drug: AZD5363
Drug: cyclophosphamide
Drug: DNA intercalators
Drug: AZD8931
Drug: Selumetinib
Drug: Methotrexate
Drug: vinca alkaloids
Drug: Vandetanib
Drug: Platinum based chemotherapies
Drug: Bicalutamide
Drug: Olaparib
Drug: Bevacizumab
Drug: Mitomycin C
Drug: Eribulin

First Posted Date: 2014-11-24

Last Posted Date: 2025-01-15

Lead Sponsor: UNICANCER

Target Recruit Count: 1460

Registration Number: NCT02299999

Locations: 🇫🇷
Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg, France
🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷
Hopitaux Du Leman, Thonon-les-Bains, France

and more 21 locations

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer Metastatic

Interventions: Drug: Standard maintenance for squamous NSCLC
Drug: AZD2014
Drug: Durvalumab
Drug: AZD4547
Drug: Pemetrexed
Drug: AZD5363
Drug: AZD8931
Drug: Selumetinib
Drug: Vandetanib
Drug: savolitinib
Drug: Olaparib

First Posted Date: 2014-04-17

Last Posted Date: 2024-01-10

Lead Sponsor: UNICANCER

Target Recruit Count: 999

Registration Number: NCT02117167

Locations: 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Institut Paoli Calmettes, Marseille, France

and more 34 locations

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1

Phase 2

Completed

Conditions: Metastatic Cancer
Solid Tumors
Hematologic Cancers

Interventions: Drug: Crizotinib

First Posted Date: 2014-01-14

Last Posted Date: 2024-02-28

Lead Sponsor: UNICANCER

Target Recruit Count: 246

Registration Number: NCT02034981

Locations: 🇫🇷
Gustave Roussy, Villejuif, Ile De France, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy